Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts.


Journal

European journal of preventive cardiology
ISSN: 2047-4881
Titre abrégé: Eur J Prev Cardiol
Pays: England
ID NLM: 101564430

Informations de publication

Date de publication:
22 05 2021
Historique:
received: 29 10 2019
accepted: 05 02 2020
entrez: 22 5 2021
pubmed: 23 5 2021
medline: 15 12 2021
Statut: ppublish

Résumé

The association between caffeinated coffee consumption and atrial fibrillation remains unclear. Recent studies suggest an inverse association only between a moderate caffeinated coffee consumption and atrial fibrillation, but others have reported no association. The aim of our study was to prospectively assess the association between caffeinated coffee consumption and atrial fibrillation in two Spanish cohorts, one of adults from a general population and another of elderly participants at high cardiovascular risk. We included 18,983 and 6479 participants from the 'Seguimiento Universidad de Navarra' (SUN) and 'Prevención con Dieta Mediterránea' (PREDIMED) cohorts, respectively. Participants were classified according to their caffeinated coffee consumption in three groups: ≤3 cups/month, 1-7 cups/week, and >1 cup/day. We identified 97 atrial fibrillation cases after a median follow-up of 10.3 years (interquartile range 6.5-13.5), in the SUN cohort and 250 cases after 4.4 years median follow-up (interquartile range 2.8-5.8) in the PREDIMED study. No significant associations were observed in the SUN cohort although a J-shaped association was suggested. A significant inverse association between the intermediate category of caffeinated coffee consumption (1-7 cups/week) and atrial fibrillation was observed in PREDIMED participants with a multivariable-adjusted hazard ratio = 0.53 (95% confidence interval 0.36-0.79) when compared with participants who did not consume caffeinated coffee or did it only occasionally. No association was found for higher levels of caffeinated coffee consumption (>1 cup per day), hazard ratio = 0.79 (95% confidence interval 0.49-1.28). In the meta-analysis of both PREDIMED and SUN studies, the hazard ratio for intermediate consumption of caffeinated coffee was 0.60 (95% confidence interval 0.44-0.82) without evidence of heterogeneity. Similar findings were found for the association between caffeine intake and atrial fibrillation risk. Intermediate levels of caffeinated coffee consumption (1-7 cups/week) were associated with a reduction in atrial fibrillation risk in two prospective Mediterranean cohorts.

Identifiants

pubmed: 34021573
pii: 6280816
doi: 10.1177/2047487320909065
doi:

Substances chimiques

Coffee 0

Banques de données

ClinicalTrials.gov
['NCT02669602']
ISRCTN
['ISRCTN35739639']

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

648-657

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL118264
Pays : United States

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

P Bazal (P)

Department of Preventive Medicine and Public Health, University of Navarra, Spain.
Servicio Navarro de Salud-Osasunbidea, Spain.

A Gea (A)

Department of Preventive Medicine and Public Health, University of Navarra, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.

A M Navarro (AM)

Department of Preventive Medicine and Public Health, University of Navarra, Spain.
Servicio Navarro de Salud-Osasunbidea, Spain.

J Salas-Salvadó (J)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Unitat de Nutriciœ Humana, Hospital Universitari San Joan de Reus, Institut d'Investigació Pere Virgili (IISPV), Spain.

D Corella (D)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Department of Preventive Medicine, University of Valencia, Spain.

A Alonso-Gómez (A)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Department of Cardiology, University Hospital Araba, Spain.

M Fitó (M)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Cardiovascular Risk and Nutrition (Regicor Study Group), Hospital del Mar Medical Research Institute (IMIM), Spain.

C Muñoz-Bravo (C)

Department of Public Health, University of Malaga, Spain.

R Estruch (R)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Department of Internal Medicine, Institut d'Investigacions Biomèdiques, August Pi i Sunyer Hospital Clinic, University of Barcelona, Spain.

M Fiol (M)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Illes Balears Health Research Institute (IdISBa), Spain.

J Lapetra (J)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria de Sevilla, Spain.

L Serra-Majem (L)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria and CHUIMI Canarian Health Service, Spain.

E Ros (E)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Endocrinology and Nutrition Service, Institut d'Investigacions Biomèdiques August Pi Sunyer, Hospital Clinic, Spain.

J Rekondo (J)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Department of Cardiology, University Hospital Araba, Spain.

M A Muñoz (MA)

Gerència Territorial de Barcelona, Institut Català de la Salut, Spain.
Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Spain.

J Basora (J)

Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, Unitat de Nutriciœ Humana, Hospital Universitari San Joan de Reus, Institut d'Investigació Pere Virgili (IISPV), Spain.

J V Sorlí (JV)

CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Department of Preventive Medicine, University of Valencia, Spain.

E Toledo (E)

Department of Preventive Medicine and Public Health, University of Navarra, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.

M A Martínez-González (MA)

Department of Preventive Medicine and Public Health, University of Navarra, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.
Department of Nutrition, Harvard TH Chan School of Public Health, USA.

M Ruiz-Canela (M)

Department of Preventive Medicine and Public Health, University of Navarra, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH